Global /Japan /Healthcare /Drug Manufacturers - General /4596

Kubota Pharmaceutical Holdings Co., Ltd.

4596

• TSE: 4596 • Delayed

92JPY -2.1%

0.5737 USD

As of 12 June 2026, Kubota Pharmaceutical Holdings Co., Ltd. has a market cap of $67.59M USD, ranking #28333 globally and #2560 in Japan. It ranks #2563 in the Healthcare sector, and #916 in the Drug Manufacturers - General industry.

Global Rank

28333

Country Rank

2560

Sector Rank

2563

Industry Rank

916

Key Stats

Market Cap

$67.59MUSD

10.85B JPY

Enterprise Value

$55.82MUSD

8.95B JPY

Revenue (TTM)

$130.84KUSD

21.0M JPY

EBITDA (TTM)

-$4.95MUSD

-793.0M JPY

Net Income (TTM)

-$4.21MUSD

-676.0M JPY

PS Ratio

516.6

PB Ratio

6.0

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ryo Kubota open_in_new

Employees

Founded

2002

Website

kubotaholdings.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	-8.7%	-7.8%	13%	54%	124%	109%	-12%	-64%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4596 窪田製薬ホールディングス株式会社 ISIN: JP3266500002 Shares Out.: Shares Outstanding: 140.244M¹ Shares Float: 84.839M² TV: TradingView: TSE: 4596 SA: Stock Analysis: TYO: 4596 YF: Yahoo Finance: 4596.T GF: Google Finance: TYO: 4596 BA: Barron's: 4596 MS: Morningstar: XTKS: 4596	92 JPY	TV: TradingView: TSE: 4596 SA: Stock Analysis: TYO: 4596 YF: Yahoo Finance: 4596.T GF: Google Finance: TYO: 4596 BA: Barron's: 4596 MS: Morningstar: XTKS: 4596

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Holdings Co., Ltd. engages in the pharmaceutical and medical device business worldwide. The company offers eyeMO, a remote retinal monitoring device for home-based and patient self-monitoring optical coherence tomography; and a NASA high-res version OCT device. It also provides Emixustat HCI compounds for Stargardt disease indications in Phase 3 clinical trials, as well as proliferative diabetic retinopathy and diabetic macular edema in Phase 2 clinical trials. The company was founded in 2002 and is headquartered in Minato, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.42B 13.07T JPY 120K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.06B 8.36T JPY 77K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.73B 5.9T JPY 54K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.28B 4.86T JPY 45K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.74B 4.13T JPY 38K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.86B 2.71T JPY 25K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 810K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 533K%	97.4	United States
Roche Holding AG SIX: RO	$320.56B 256.25B CHF 474K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.45B 215.59B GBP 427K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 405K%	15.1	United States

chevron_leftBack